Administrative regulation-informed analysis of the developmental path of national volume-based procurement to improve drug accessibility in China
Bibliographic Data
| ID | 22078992 |
|---|---|
| Authors | Songxin Lu (Shenzhen Polytechnic University), Xiangdong Liu (0000-0002-9303-5709, Macao Polytechnic University), Zhengzong Huang (0000-0002-0542-4860, Shenzhen Technology University, corresponding author), Zhiheng Zhou (0000-0003-4269-5173, Southern Medical University Shenzhen Hospital), Zehua Feng (0000-0002-6838-0893, Guangdong University of Technology) |
| Year | 2024 |
| Volume | 12 |
| Pages | 1342632-1342632 |
| Publication date | 2024-07-10 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2024.1342632 |
| PMID | 39050613 |
| OpenAlex | W4400513778 |
| Language | EN |
| Citations received | 1 |
| References cited | 13 |
Introduction: The procurement of medicines via China's national volume-based procurement (NVBP) necessitates collaboration among various entities. This paper highlights the legal significance of the engagement of pharmaceutical companies, hospitals, and the National Healthcare Security Administration (NHSA) in improving drug accessibility. Methods: We conducted a numerical simulation using MATLAB to develop an evolutionary game model involving these three participants in NVBP. Results: Our findings indicate that the final evolutionary stabilization strategies are pharmaceutical companies actively participating, hospitals using bid-winning medicines, and the NHSA implementing a low-intensity intervention. The study reveals that the evolutionary outcomes for hospitals and pharmaceutical companies are significantly affected by factors such as NHSA's subsidy level and pharmaceutical companies' level of participation. However, NHSA's decision-making process is less influenced by these factors. Discussion: From a legal perspective, the successful implementation of NVBP, ensuring fairness and legality, requires adherence to relevant policies and regulations. The NHSA should employ statutory incentives and regulatory methods in formulating and adjusting NVBP policy to enable pharmaceutical companies, hospitals, and the NHSA to exercise their rights rationally within the legal framework of the game process
Business · China · Political science · Procurement · Health Systems, Economic Evaluations, Quality of Life · Healthcare Systems and Reforms · Law · Medicine · Pharmaceutical Economics and Policy · Marketing
| Citations per year | 1 |
|---|---|
| Citation span | 2025 - 2025 (1) |
| Highly cited | No |